[1]肖涟波△,黄慈波△,陈卫衡,等.痛风性关节炎/痛风石外科诊疗专家共识[J].中国中医骨伤科杂志,2026,34(02):1-11.[doi:10.20085/j.cnki.issn1005-0205.260201]
　XIAO Lianbo,HUANG Cibo,CHEN Weiheng,et al.Expert Consensus on Surgical Management of Gouty Arthritis/Tophi[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2026,34(02):1-11.[doi:10.20085/j.cnki.issn1005-0205.260201]
点击复制

痛风性关节炎/痛风石外科诊疗专家共识()

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第34卷
期数:
2026年02期
页码:
1-11
栏目:
专家共识
出版日期:
2026-02-15

文章信息/Info

Title:
Expert Consensus on Surgical Management of Gouty Arthritis/Tophi
文章编号:
1005-0205(2026)02-0001-11
作者:
肖涟波1; 2△; 黄慈波3△; 陈卫衡4; 雷光华5; 凌光辉6; 于杰7; 薛愉8; 卢启贵9; 许鹏10; 杨功旭11; 金群华12; 接力刚13; 糜菁熠14; 何东仪1; 2; 戴生明15; 陶金辉16; 戴号1; 2; 沈军1; 2; 程少丹1; 2
1上海市光华中西医结合医院(上海,200052);2上海市中医药研究院关节病研究所;3深圳大学附属华南医院;4北京中医药大学附属第三医院;5中南大学湘雅医院;6中南大学湘雅二医院;7中国中医科学院望京医院;8复旦大学附属华山医院;9深圳市罗湖区中医院;10西安市儿童医院;11湖北省中医院;12宁夏医科大学总医院;13南方医科大学珠江医院;14无锡市第九人民医院;15上海市第六人民医院;16中国科学技术大学附属第一医院
Author(s):
XIAO Lianbo1; 2△; HUANG Cibo3△; CHEN Weiheng4; LEI Guanghua5; LING Guanghui6; YU Jie7; XUE Yu8; LU Qigui9; XU Peng10; YANG Gongxu11; JIN Qunhua12; JIE Ligang13; MI Jingyi14; HE Dongyi1; 2; DAI Shengming15; TAO Jinhui16; DAI Hao1; 2; SHEN Jun1; 2; CHENG Shaodan1; 2
1Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai 200052,China; 2The Institute for Joint Diseases,Shanghai Academy of Traditional Chinese Medicine,Shanghai 200052,China; 3South China Hospital Affiliated to Shenzhen University,Shenzhen 518111,Guangdong China; 4Beijing University of Chinese Medicine Third Affiliated Hospital,Beijing 100029,China; 5Xiangya Hospital of Central South University,Changsha 410008,China; 6The Second Xiangya Hospital of Central South University,Changsha 410011,China; 7Wangjing Hospital of China Academy of Chinese Medical Sciences,Beijing 100102,China; 8Huashan Hospital,Fudan University,Shanghai 200040,China; 9Shenzhen Luohu Hospital of Traditional Chinese Medicine,Shenzhen 518000,Guangdong China;.....
关键词:
痛风性关节炎;  痛风石;  外科;  诊疗;  专家共识
Keywords:
gouty arthritis;  tophi;  surgery;  diagnosis and treatment;  expert consensus
分类号:
R684.3
DOI:
10.20085/j.cnki.issn1005-0205.260201
文献标志码:
A
摘要:
痛风是一种由嘌呤代谢紊乱和(或)尿酸排泄减少导致高尿酸血症,进而引起单钠尿酸盐(MSU)晶体沉积致机体损伤的代谢性风湿病,可累及关节形成痛风性关节炎,严重影响患者生存质量。尽管降尿酸药物治疗体系在痛风性关节炎/痛风石管理中已发挥了重要作用,但对软组织和(或)关节中的痛风石所导致的结构严重破坏、功能受限或保守治疗无效的顽固性疼痛,通常需要外科干预。为系统提升痛风性关节炎/痛风石外科诊疗的规范化水平,由北京整合医学学会发起,上海市光华中西医结合医院与深圳大学附属华南医院牵头,联合上海中医药研究院关节病研究所,组织国内多家三级甲等医院风湿免疫科、关节外科及骨伤科专家,基于牛津大学循证医学中心(OCEBM)分级系统,系统评价国内外最新循证医学证据,结合我国临床实际,针对痛风性关节炎/痛风石外科干预适应证、围手术期管理、术式选择及康复等8项关键临床问题,制定本专家共识,旨在提升临床决策的有效性、科学性和规范性。
Abstract:
Gout is a metabolic rheumatic disease characterized by hyperuricemia resulting from purine metabolism disorders and/or reduced uric acid excretion,leading to monosodium urate(MSU)crystal deposition and tissue damage.It can affect joints,causing gouty arthritis and significantly impairing patients’ quality of life.Although urate-lowering drug therapy has played a significant role in managing gouty arthritis and tophi,surgical intervention is often required for severe structural damage,functional limitations,or refractory pain in soft tissues and/or joints caused by tophi that are unresponsive to conservative treatment.To systematically enhance the standardization of surgical diagnosis and treatment for gouty arthritis and tophi,the Beijing Society of Integrative Medicine initiated a collaborative effort led by Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine and South China Hospital Affiliated to Shenzhen University.In partnership with the Institute for Joint Diseases,Shanghai Academy of Traditional Chinese Medicine,experts from rheumatology,joint surgery,and orthopedic departments at multiple Grade A tertiary hospitals nationwide were organized.Based on the Oxford Centre for Evidence-Based Medicine(OCEBM)grading system,this expert consensus addresses eight critical clinical issues,including indications for surgical intervention,perioperative management,surgical technique selection,and rehabilitation by systematically evaluating the latest domestic and international evidence-based medical evidence and integrating China’s clinical realities.It aims to enhance the effectiveness,scientific rigor,and standardization of clinical decision-making.

参考文献/References:

[1] 徐东,朱小霞,邹和建,等.痛风诊疗规范[J].中华内科杂志,2023,62(9):1068-1076.
[2] SCHLESINGER N,THIELE R G.The pathogenesis of bone erosions in gouty arthritis[J].Annals of the Rheumatic Diseases,2010,69(11):1907-1912.
[3] RICHETTE P,DOHERTY M,PASCUAL E,et al.2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout[J].Annals of the Rheumatic Diseases,2020,79(1):31-38.
[4] 司可,陈颖,王颜刚.难治性痛风中西医结合治疗专家共识(2023)[J].精准医学杂志,2023,38(6):471-474.
[5] FITZGERALD J D,DALBETH N,MIKULS T,et al.2020 American college of rheumatology guideline for the management of gout[J].Arthritis Care & Research,2020,72(6):744-760.
[6] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.痛风及高尿酸血症基层诊疗指南(2019年)[J].中华全科医师杂志,2020,19(4):293-303.
[7] World Health Organization.WHO handbook for guideline development[M].2nd ed.Vienna:World Health Organization,2014:1-167.
[8] 陈耀龙,杨克虎,王小钦,等.中国制订/修订临床诊疗指南的指导原则(2022版)[J].中华医学杂志,2022,102(10):697-703.
[9] University of Oxford.Centre for evidence-based medicine levels of evidence[EB/OL].Oxford:University of Oxford,2009.
[10] SHEA B J,GRIMSHAW J M,WELLS G A,et al.Development of AMSTAR:a measurement tool to assess the methodological quality of systematic reviews[J].BMC Medical Research Methodology,2007,7(1):10.
[11] HIGGINS J P T,ALTMAN D G,G?TZSCHE P C,et al.The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials[J].BMJ,2011,343:d5928.
[12] WHITING P F,RUTJES A W S,WESTWOOD M E,et al.QUADAS-2:a revised tool for the quality assessment of diagnostic accuracy studies[J].Annals of Internal Medicine,2011,155(8):529-536.
[13] WELLS G A,WELLS G,SHEA B,et al.The Newcastle-Ottawa scale(NOS)for assessing the quality of nonrandomised studies in meta-analyses[EB/OL].Ottawa:Ottawa Hospital Research Institute,2014.
[14] FITZGERALD J D.Gout[J].Annals of Internal Medicine,2025,178(3):ITC33-ITC48.
[15] OGDIE A,TAYLOR W J,WEATHERALL M,et al.Imaging modalities for the classification of gout:systematic literature review and meta-analysis[J].Annals of the Rheumatic Diseases,2015,74(10):1868-1874.
[16] CARCIONE J,BODOFSKY S,LAMOREAUX B,et al.Beyond medical treatment:surgical treatment of gout[J].Current Rheumatology Reports,2020,23(1):1.
[17] RICHETTE P,DOHERTY M,PASCUAL E,et al.2016 updated EULAR evidence-based recommendations for the management of gout[J].Annals of the Rheumatic Diseases,2017,76(1):29-42.
[18] YIP R M,CHEUNG T T,SO H,et al.The Hong Kong Society of Rheumatology consensus recommendations for the management of gout[J].Clinical Rheumatology,2023,42(8):2013-2027.
[19] LAINE L,SMITH R,MIN K,et al.Systematic review:the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs[J].Alimentary Pharmacology & Therapeutics,2006,24(5):751-767.
[20] NIDORF S M,FIOLET A T L,MOSTERD A,et al.Colchicine in patients with chronic coronary disease[J].New England Journal of Medicine,2020,383(19):1838-1847.
[21] LIU D,AHMET A,WARD L,et al.A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy[J].Allergy,Asthma & Clinical Immunology,2013,9(1):30.
[22] LATOURTE A,PASCART T,FLIPO R M,et al.2020 recommendations from the French Society of Rheumatology for the management of gout:management of acute flares[J].Joint Bone Spine,2020,87(5):387-393.
[23] HUI M,CARR A,CAMERON S,et al.The British society for rheumatology guideline for the management of gout[J].Rheumatology,2017,56(7):e1-e20.
[24] SAAG K G,KHANNA P P,KEENAN R T,et al.A randomized,phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares[J].Arthritis & Rheumatology,2021,73(8):1533-1542.
[25] SUNDY J S,SCHUMACHER H R,KIVITZ A,et al.Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy:results of RESURGE,a phase III,international safety study[J].The Journal of Rheumatology,2014,41(8):1703-1711.
[26] SCHLESINGER N,ALTEN R E,BARDIN T,et al.Canakinumab for acute gouty arthritis in patients with limited treatment options:results from two randomised,multicentre,active-controlled,double-blind trials and their initial extensions[J].Annals of the Rheumatic Diseases,2012,71(11):1839-1848.
[27] XUE Y,CHU T S,HU J K,et al.Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy:a randomized phase 3 trial[J].The Innovation,2025,6(8):101015.
[28] KONG N,XUE Y,MAO L,et al.Efficacy and safety of firsekibart compared to etoricoxib for gout flares:a phase 2,multicenter,open-label,active-controlled,randomized non-inferiority trial[J].Rheumatology and Therapy,2025,12(5):975-990.
[29] SCHLESINGER N,PILLINGER M H,SIMON L S,et al.Interleukin-1β inhibitors for the management of acute gout flares:a systematic literature review[J].Arthritis Research & Therapy,2023,25(1):128.
[30] 朱坤智,卢涛,罗张风,等.四肢痛风石外科治疗时机和适应证[J].中国组织工程研究,2021,25(30):4883-4890.
[31] 中华医学会骨科学分会.中国骨科手术加速康复围手术期疼痛管理专家共识[J].中华骨与关节外科杂志,2022,15(10):721-730.
[32] 中国加速康复外科专家组.中国加速康复外科围手术期非甾体抗炎药临床应用专家共识[J].中华普通外科杂志,2019,34(3):283-288.
[33] 中华医学会外科学分会.中国普通外科围手术期血栓预防与管理指南[J].中华外科杂志,2016,54(5):321-327.
[34] 中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志,2020,36(1):1-13.
[35] STAMP L K,CHAPMAN P T,BARCLAY M L,et al.A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout[J].Annals of the Rheumatic Diseases,2017,76(9):1522-1528.
[36] BORSTAD G C,BRYANT L R,ABEL M P,et al.Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis[J].The Journal of Rheumatology,2004,31(12):2429-2432.
[37] YAMANAKA H,TAMAKI S,IDE Y,et al.Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy:results from FORTUNE-1,a prospective,multicentre randomised study[J].Annals of the Rheumatic Diseases,2018,77(2):270-276.
[38] ZOU H,XUE Y,HU J,et al.Genakumab reduces the risk of acute gout flares during initiation of urate-lowering therapy:a phase 2,randomized,open-label,multi-center,active-controlled clinical trial[J].Annals of the Rheumatic Diseases,2025,84:238-239.
[39] HERSHFIELD M S,CALLAGHAN J T,TASSANEEYAKUL W,et al.Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing[J].Clinical Pharmacology and Therapeutics,2013,93(2):153-158.
[40] WHITE W B,SAAG K G,BECKER M A,et al.Cardiovascular safety of febuxostat or allopurinol in patients with gout[J].The New England Journal of Medicine,2018,378(13):1200-1210.
[41] ZHAO L,CAO L,ZHAO T Y,et al.Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies:a systematic review and meta-analysis[J].Chinese Medical Journal,2020,133(8):982-993.
[42] YANAI H,ADACHI H,HAKOSHIMA M,et al.A possible therapeutic application of the selective inhibitor of urate transporter 1,dotinurad,for metabolic syndrome,chronic kidney disease,and cardiovascular disease[J].Cells,2024,13(5):450.
[43] SCHLESINGER N,LIPSKY P E.Pegloticase treatment of chronic refractory gout:update on efficacy and safety[J].Seminars in Arthritis and Rheumatism,2020,50(3S):S31-S38.
[44] XUE X M,LIU Z,LI X D,et al.The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone:a prospective,randomized controlled study[J].Rheumatology,2021,60(6):2661-2671.
[45] SOWISKA I,SOWISKI R,RUTKOWSKA-SAK L.Tophi-surgical treatment[J].Rheumatology,2016,54(5):267-272.
[46] COHEN-ROSENBLUM A R,SOMOGYI J R,HYNES K K,et al.Orthopaedic management of gout[J].Journal of the American Academy of Orthopaedic Surgeons:Global Research & Reviews,2022,6(11):e22.00216.
[47] TANG B,ZENG X Z,FAN C.Significantly better efficacy for acute ankle gouty arthritis through arthroscopic debridement compared with simple drug therapy:a longitudinal study with 1-year follow-up[J].Journal of Clinical Rheumatology,2022,28(1):e69-e72.
[48] WANG C C,LIEN S B,HUANG G S,et al.Arthroscopic elimination of monosodium urate deposition of the first metatarsophalangeal joint reduces the recurrence of gout[J].Arthroscopy,2009,25(2):153-158.
[49] 荆兆峰,赵以瑜,滕立玲,等.关节镜下清理病灶联合置管灌洗术治疗急性膝关节痛风性关节炎35例[J].山东医药,2008,48(15):82.
[50] 潘羽生.微创针刀镜治疗膝关节痛风性关节炎的疗效观察[D].广州:广州中医药大学,2016.
[51] 接力刚,韦嵩,陈志煌,等.微创针刀镜治疗难治性膝关节急性痛风性关节炎的临床疗效[J].新医学,2017,48(6):395-398.
[52] LI E K,TAM L S,WONG R W,et al.Tophaceous gout causing carpal tunnel syndrome:report of three cases and literature review[J].Clinical Rheumatology,2000,19(2):147-149.
[53] HOLBROOK H S,CALANDRUCCIO J H.Management of gout in the hand and wrist[J].The Orthopedic Clinics of North America,2023,54(3):299-308.
[54] CHANDRATRE P,RODDY E,CLARSON L,et al.Health-related quality of life in gout:a systematic review[J].Rheumatology,2013,52(11):2031-2040.
[55] ZHELIABINA O V,ELISEEV M S,GLUKHOVA S I,et al.Contributing factors of diabetes mellitus among patients with gout(results of the long-term prospective study)[J].Doklady Biochemistry and Biophysics,2023,511(1):195-202.
[56] LIANG H S,HUANG J W,CUI H W,et al.Spinal endoscopic surgery for tophi in the lumbar spinal canal:a case report[J].Asian Journal of Surgery,2024,47(4):2052-2053.
[57] 陈浩宇,高峻青,黄昭华,等.痛风引起腕管综合征诊疗的临床研究[J].中国矫形外科杂志,2021,29(7):653-655.
[58] 邓利超,王永成,陈城,等.痛风性炎症发作肌腱受累的研究进展[J].中国老年学杂志,2025,45(10):2545-2550.
[59] 王国忠,路超,屈志刚,等.游离掌长肌腱移植重建术治疗腕手部屈肌腱痛风石侵蚀病变疗效观察[J].中国修复重建外科杂志,2025,39(3):278-283.
[60] ADAHAN H M,SHARON H,SIEV-NER I.A sound solution to tendonitis:healing tendon tears with a novel low-intensity,low-frequency surface acoustic ultrasound patch[J].PM&R,2010,2(7):685-687.
[61] 李武平,王林华,周富强,等.Ilizarov关节成形术治疗第一跖趾关节痛风性骨破坏[J].中国矫形外科杂志,2019,27(5):470-473.
[62] FITZGERALD B T,SETTY A,MUDGAL C S.Gout affecting the hand and wrist[J].Journal of the American Academy of Orthopaedic Surgeons,2007,15(10):625-635.
[63] 王凌椿,潘培军,陈杰伟,等.骨水泥间隔器重建第一跖趾关节痛风性骨缺损的疗效分析[J].足踝外科电子杂志,2022,9(1):54-59.
[64] ZHANG Z C,YANG H Z,XU Z W,et al.Total hip arthroplasty outcomes in patients with gout:a retrospective analysis of matched large cohorts[J].Clinics in Orthopedic Surgery,2024,16(4):542-549.
[65] CHEN C L,SHAO H Y,BLOCK J L,et al.Greater wound and renal complications in gout patients undergoing total joint arthroplasty[J].The Journal of Arthroplasty,2016,31(7):1431-1436.
[66] LIU F,HUANG R K,XIE M,et al.Use of Masquelet’s technique for treating the first metatarsophalangeal joint in cases of gout combined with a massive bone defect[J].Foot and Ankle Surgery,2018,24(2):159-163.
[67] 陈军明,马文泽,徐华,等.微型锁定钢板关节融合术治疗第1跖趾关节痛风性关节炎伴感染疗效分析[J].山西医药杂志,2021,50(18):2645-2647.
[68] 秦博泉,吴仕舟,解慧琪,等.病灶清除联合Ilizarov技术治疗第一跖趾关节痛风石合并骨缺损[J].中国修复重建外科杂志,2020,34(2):168-172.
[69] KASPER I R,JURIGA M D,GIURINI J M,et al.Treatment of tophaceous gout:when medication is not enough[J].Seminars in Arthritis and Rheumatism,2016,45(6):669-674.
[70] 肖顺娥,李海,张天华,等.抗生素骨水泥植入联合游离嵌合组织瓣移植序贯治疗严重痛风性创面的临床效果[J].中华烧伤与创面修复杂志,2025,41(1):53-60.
[71] 中国老年医学学会烧创伤分会.老年急性创伤性创面评估和治疗的专家共识(2025版)[J].中华烧伤与创面修复杂志,2025,41(9):825-839.
[72] WANG P,HE Y J,WANG J H,et al.Experience of VSD in the treatment of foot tophi rupture with severe infection wounds[J].Chinese Journal of Plastic and Reconstructive Surgery,2019,1(2):5-11.
[73] 龚喜龙,杨光,孙鸿斌,等.四肢多发痛风石患者手术治疗临床效果分析(附23例报告)[J].吉林大学学报(医学版),2018,44(2):394-397.
[74] 张博,任世祥,林源.关节镜下重建治疗痛风性前交叉韧带损伤的临床效果[J].第二军医大学学报,2021,42(8):937-940.
[75] 国家卫生健康委加速康复外科专家委员会骨科专家组,中国研究型医院学会骨科加速康复专业委员会,中国康复技术转化及促进会骨科加速康复专业委员会,等.骨科加速康复手术切口操作与并发症防治专家共识[J].中华骨与关节外科杂志,2022,15(10):776-784.
[76] 中国康复技术转化及发展促进会,中华医学会麻醉学分会,中国医师协会麻醉学医师分会,等.骨科、麻醉科加速康复围手术期疼痛、睡眠和焦虑障碍管理专家共识[J].中华骨与关节外科杂志,2025,18(3):212-221.
[77] 中国康复技术转化及发展促进会,中华医学会麻醉学分会,中国医师协会麻醉学医师分会,等.市县医院骨科、麻醉科加速康复实施管理专家共识[J].中华骨与关节外科杂志,2025,18(3):200-211.
[78] 罗洁.防己黄芪汤加味治疗非急性期痛风性关节炎脾虚湿阻证的临床疗效观察[D].乌鲁木齐:新疆医科大学,2024.
[79] 甘斌,李华南,章晓云,等.中药单体治疗痛风性关节炎研究进展[J].中华中医药杂志,2022,37(10):5848-5852.
[80] 何伟东,周中,黄海涛,等.中药汤剂联合关节镜治疗膝关节痛风性关节炎临床观察[J].云南中医中药杂志,2021,42(10):95-96.
[81] 罗玉明,谢杰,沈庆亮,等.关节镜清理配合术后中药封包治疗反复发作性膝痛风性关节炎的疗效观察[J].中国医药科学,2022,12(24):161-164.
[82] 王建琼.艾灸联合中药涂擦对痛风性关节炎急性期患者的应用效果[J].西藏医药,2025,46(1):170-172.
[83] 文斌.电针联合清热止痛膏外敷治疗急性痛风性关节炎的临床观察[D].武汉:湖北中医药大学,2021.
[84] 马文婧,熊燕,李箭.痛风性膝关节炎关节镜术后谨防痛风急性发作和术后感染的误诊误治[J].中国骨伤,2024,37(7):664-669.
[85] 宋小雯.延续性护理干预对痛风性关节炎患者术后康复的影响[J/OL].中华关节外科杂志(电子版),2021,15(3):387-390.
(收稿日期:2025-10-23)

备注/Memo

备注/Memo:
△通信作者 E-mail:13701888178@163.com(肖涟波)
15810999904@139.com(黄慈波)
更新日期/Last Update: 2026-02-15